MODIFICATION TO SCOOPER DRUG/ADULTERATION TEST CUP

K013124 · Branan Medical Corp. · DJJ · Nov 7, 2001 · Clinical Toxicology

Device Facts

Record IDK013124
Device NameMODIFICATION TO SCOOPER DRUG/ADULTERATION TEST CUP
ApplicantBranan Medical Corp.
Product CodeDJJ · Clinical Toxicology
Decision DateNov 7, 2001
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 862.3640
Device ClassClass 2

Indications for Use

The Scooper™ Drug/Adulterant Test Cup is an in vitro screen test for the rapid detection of morphine, amphetamines, 11-nor-A9-Tetrahydrocannabinol-9-carboxylic acid, benzoylecgonine and phencyclidine in human urine. The cutoff concentrations are as follows: OPI Morphine 2000 ng/ml; AMP Amphetamines 1000 ng/ml; THC 11-nor-A9-Tetrahydrocannabinol-9-carboxylic acid 50 ng/ml; COC Benzoylecgonine 300 ng/ml; PCP Phencyclidine 25 ng/ml. The Scooper™ Drug/Adulteration Test Cup is used to obtain visual, qualitative results. The Scooper™ Drug/Adulteration Test Cup is not for over-the-counter sale to lay persons.

Device Story

Scooper™ Drug/Adulteration Test Cup is an in vitro diagnostic device for urine drug screening. It utilizes integrated test strips for the detection of morphine, amphetamines, THC, cocaine metabolite, and phencyclidine, alongside reagent pads for adulteration testing (creatinine, nitrite, pH, oxidizing agents). The device is a self-contained cup; urine is collected directly into the cup by the user. Results are visual and qualitative, interpreted by a healthcare professional or technician. The device provides rapid screening to assist in clinical decision-making regarding substance use. It is intended for professional use in clinical settings.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on bench testing of analytical performance, including sensitivity, specificity, and cutoff verification for the specified drug analytes and adulteration parameters.

Technological Characteristics

Lateral flow immunoassay test strips for drug detection; colorimetric reagent pads for adulteration testing (creatinine, nitrite, pH, oxidizing agents). Integrated cup form factor. Standalone device; no electronic components, software, or connectivity.

Indications for Use

Indicated for the rapid, qualitative, in vitro detection of morphine, amphetamines, THC metabolite, benzoylecgonine, and phencyclidine in human urine, along with adulteration testing for creatinine, nitrite, pH, and oxidizing agents. Intended for professional use; not for over-the-counter sale.

Regulatory Classification

Identification

A morphine test system is a device intended to measure morphine, an addictive narcotic pain-relieving drug, and its analogs in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of morphine use or overdose and in monitoring levels of morphine and its analogs to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). A morphine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three horizontal lines representing its wings. The eagle is positioned within a circular border, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the upper portion of the circle. Re: Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Mr. Raphael Wong President Branan Medical Corporation 10015 Muirlands Road - Suite E Irvine, CA 92618 NOV 0 7 2001 k013124 Trade/Device Name: Scooper TM Drug/Adulteration Test Cup-MOR/AMP/THC/COC/PCP Drug Screen Tests with Adulteration Pads for Creatinine, Nitrite, pH and Oxidizing Agents Regulation Number: 21 CFR 862.3650; 21 CFR 862.3100; 21 CFR 862.3870; 21 CFR 862.3250 Regulation Name: Opiate test system; Amphetamine test system; Cannabinoid test system; Cocaine and cocaine metabolite test system Regulatory Class: Class II; Class II; Class II, Class II Product Code: DJJ; DKZ; LDJ; DIO Dated: October 18, 2001 Received: October 22, 2001 Dear Mr. Wong: We have reviewed your Section 510(k) premarket notification of intent to market the device we nave roviewed your be determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for the building to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it 11 your de roo is exactional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {1}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed noaticate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (Jory Sy Hot the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Sutman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ K013124 NOV 0 7 2001 1 Page ← of 510(k) Number (if known): /~~K013124~~ Scooper™ Drug/Adulteration Test Cup -Device Name: MOR/AMP/THC/COC/PCP Drug Screen Tests with MONAMI / HEPCOCH OF Creatinine, Nitrite, pH and Oxidizing Agents Indications For Use: The Scooper™ Drug/Adulterant Test Cup is an in vitro screen test for the rapid detection. The west The Scooper -- Drug/Adulterail: Test Sup Sup son and phencyclidine in human urine. The cutoff concentrations are as follows: | OPI | Morphine | 2000 ng/m | |-----|--------------------------------------------------|-----------| | AMP | Amphetamines | 1000 ng/m | | THC | 11-nor-A9-Tetrahydrocannabinol-9-carboxylic acid | 50 ng/m | | COC | Benzoylecgonine | 300 ng/m | | PCP | Phencyclidine | 25 ng/m | The Scooper™ Drug/Adulteration Test Cup is used to obtain visual, qualitative results The Scooper - Drug/Additeration 2001 Super-the-counter sale to lay persons. Alan Cooper (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number K013124 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) | Concurrence of CDRH, Office of Device Evaluation (ODE) | | | |--------------------------------------------------------|----|--------------------------------------------------| | Prescription Use<br>(Per 21 CFR 801.109) | OR | Over-The-Counter Use<br>(Optional Format 1-2-96) |
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...